Clinical trial
Effects of Exenatide and Insulin Glargine in Subjects With Type 2 Diabetes
NCT00097500 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00097500 |
|---|---|
| Title | Effects of Exenatide and Insulin Glargine in Subjects With Type 2 Diabetes |
| Official title | A Phase 3, Randomized, Open Label, Comparator-Controlled, Parallel Group, Multicenter Study to Compare the Effects of Exenatide and Insulin Glargine on Beta Cell Function and Cardiovascular Risk Markers in Subjects With Type 2 Diabetes Treated With Metformin Who Have Not Achieved Target HbA1c |
| Lead sponsor | AstraZeneca, Industry |
| Collaborators | Eli Lilly and Company Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Type 2 Diabetes Mellitus |
| Intervention type | Drug |
| Interventions | exenatide, Insulin glargine, Metformin |
| Enrollment | 69 |
| Start date | Sep 1, 2004 |
| Primary completion | Dec 1, 2009 |
| Completion | Dec 1, 2009 |
| First posted | Nov 25, 2004 |
| Last update posted | Apr 7, 2015 |
| Countries | Finland, Netherlands, Sweden |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: